460 research outputs found
ZNS-Tumoren
No full textKaum ein medizinisches Forschungsgebiet ist einem so raschen Wandel unterzogen, wie das der Onkologie. Die wichtigsten Erkenntnisse zu gesichertem und vorläufigem Wissen in den jeweils letzten zwölf Monaten übersichtlich darzustellen ist Anliegen dieser Buchreihe. Im Update Hämatologie / Onkologie 2010 versammeln renommierte Autoren die aktuellen Forschungsergebnisse und Therapiekonzepte für Klinik und Praxis. In das diesjährige Update neu aufgenommen wurden Übersichtsarbeiten zu ZNS- und Kopf-Hals-Tumoren sowie zu Weichteilsarkomen. Verantwortliche Herausgeber sind Stephan Petrasch, Chefarzt der Klinik für Innere Medizin am Klinikum Duisburg, und Gerhard Ehninger, geschäftsführender Vorsitzender der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO) und Direktor der Medizinischen Klinik und Poliklinik I am Universitätsklinikum Carl Gustav Carus in Dresden
ZNS-Tumoren
No full textForschung und Fortschritt schreiten in kaum einem anderen Fachgebiet der Medizin so rasant voran wie in der Onkologie. Die wichtigsten Erkenntnisse zu gesichertem und vorläufigem Wissen in den jeweils letzten zwölf Monaten übersichtlich darzustellen ist Anliegen dieser Buchreihe. Im Update Hämatologie / Onkologie 2014 stellen renommierte Autoren die aktuellen Forschungsergebnisse und Therapiekonzepte für Klinik und Praxis zusammen. In 12 Kapiteln erfahren interessierte Ärzte zu hämatologischen Erkrankungen, zu den wichtigsten soliden Tumoren sowie zur Supportivtherapie inklusive Palliativmedizin alles, was wichtig war in den vorangegangenen zwölf Monaten. Verantwortliche Herausgeber sind Stephan Petrasch, Chefarzt der Klinik für Innere Medizin am Klinikum Duisburg, und Gerhard Ehninger, Direktor der Medizinischen Klinik und Poliklinik I am Universitätsklinikum Carl Gustav Carus in Dresden
Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid
No full textPurpose: To detect possible interactions between (-)-formyl-tetrahydrofolic acid (leucovorin, (-)-fTHF) and (+)-formyl-tetrahydrofolic acid ((+)-fTHF) on the plasma and intracellular pharmacokinetics following their simultaneous administration. Methods: Plasma levels of (-)-fTHF, (-)-methyl-THF, and (+)-fTHF were determined in samples from four volunteers following the administration of both (-)-fTHF and (+/-)-fTHF and in seven patients during a 5-fluorouracil (5-FU)/fTHF combination chemotherapy. In addition, the intracellular uptake of C-14-(-)-mTHF in the presence of (+)-mTHF at increasing concentrations was measured in vitro. Analyses were performed using a highly specific high-performance liquid chromatography procedure. Results: The pharmacokinetic parameters obtained for (-)-fTHF following the administration of (-)-fTHF only were: terminal half-life, 1.2 h; area under the curve, 10 mu g.h/ml; maximum concentration, 12 mu g/ml; clearance, 305 ml/min; volume of distribution, 19 l. The parameters did not differ significantly as compared with those obtained following the administration of (+/-)-fTHF to both volunteers and patients. There were no differences in the pharmacokinetics of (-)-mTHF or in the protein binding of both substances with the different forms of administration. The intracellular uptake of C-14- (-)-mTHF did not depend on the presence of (+)-mTHF at either concentration. Conclusions: These data suggest that (-)-fTHF is not therapeutically superior to (+/-)-fTHF and that the latter is appropriate during combination chemotherapy with 5-FU/fTHF in patients with colorectal cancers
Plasma levels of granulocyte colony-stimulating factor in patients after allogeneic bone marrow transplantation for chronic myeloid leukemia correlate with engraftment of transplanted marrow
No full textBusch FW, Pilgrim TB, Krämer A, Ehninger G. Plasma levels of granulocyte colony-stimulating factor in patients after allogeneic bone marrow transplantation for chronic myeloid leukemia correlate with engraftment of transplanted marrow. Bone Marrow Transplantation. 1997;19(7):653-659.Granulocyte colony-stimulating factor (G-CSF) is considered to play a pivotal role in hemopoietic regulation, Its pharmacological application is reported to shorten chemotherapy-induced neutropenia as well as time to engraftment in patients after bone marrow transplantation (BRIT), In order possibly to establish further rationale for G-CSF treatment strategies in patients undergoing BMT, me evaluated G-CSF plasma levels of 89 patients after allogeneic BMT for chronic myeloid leukemia (Chit), EDTA anti-coagulated plasma samples were collected starting on day -1 (before grafting) and thereafter twice weekly for four consecutive weeks, G-CSF levels were estimated by enzyme immunoassay. Patients with late (>30 days) bone marrow engraftment had consistently higher G-CSF levels at day +1 (after grafting) compared to patients with early (less than or equal to 30 days) engraftment, while all patients had low plasma levels on day -1/0. Mean G-CSF plasma levels and time to engraftment were correlated (r = 0.79), In univariate analyses, high G-CSF levels at days +1, +4, +7, +10 and several clinical variables (such as TBI, unrelated donor transplant, state of disease) were predictive of late engraftment, Further analysis by multivariate Cos regression resulted in the following predictive model: high G-CSF plasma levels at day +7 and +10 (after grafting), in combination with a blastic phase of the disease were highly predictive of late engraftment, The significantly higher G-CSF levels in patients with impaired engraftment may reflect early compensating mechanisms of the hemopoietic system, which should be investigated further
Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors
No full textTS gene expression, TS polymorphisms and pathological tumor regression in rectal cancer patients treated with standardized neoadjuvant chemoradiotherapy
No full textTS gene expression, TS polymorphisms and pathological tumor regression in rectal cancer patients treated with standardized neoadjuvant chemoradiotherapy
No full text
Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation
No full textUnlabelled: THE AIM of this study was to evaluate the impact of genomic polymorphisms of methylene-tetrahydrofolate-reductase (MTHFR-C677T, MTHFR-A1298C) and various glutathione S-transferases (GSTP1-Ilel05Val, GSTA1*a/b, GSTM1, GSTT1) on the occurrence of liver toxicity in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Patients and methods: Eighty-four adult patients were enrolled in this retrospective study. All patients were treated with busulfan/cyclophosphamide as a conditioning regimen and received cyclosporine and short-course MTX for GvHD prophylaxis. Genotyping was performed using PCR based restriction-fragment-length-polymorphism (RFLP) techniques. Results: Multivariate analysis identified the MTHFR-A1298C polymorphism as an independent predictor for maximum levels of bilirubin (p=0.0025) and duration of hyperbilirubinaemia (p=0.013). Furthermore, there was an association between this polymorphism and the occurrence of the sinusoidal obstruction syndrome (SOS) (p=0.048). No significant associations between the MTHFR-C677T or the various GST polymorphisms and liver toxicity were observed. Conclusion: The MTHFR-A1298C polymorphism might be associated with liver toxicity in patients receiving allogeneic HSCT
- …
